Yunkang Announces 2023 Annual Results, Revenue Reaches RMB892 Million
HONG KONG, March 25, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2023 (the "Reporting Period"). In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million. The Group's routine testing business achieved a healthy and steady year-on-year growth of 26.9% during the Reporting Period. Due to enhanced operational and management capabilities and improved cost control, the overall gross profit margin remained stable at 36.5%. The Group further improved its operational and management capabilities and strengthened its cash flow management, resulting in a significant improvement in net cash generated from operating activities as compared with last year. As at December 31, 2023, the Group's cash and cash equivalents amounted to RMB1,244.1 million. The Board of Directors resolved to recommend the payment of a final dividend of HK$0.02 per share for the year ended December 31, 2023.
- In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million.
- As at December 31, 2023, the Group's cash and cash equivalents amounted to RMB1,244.1 million.
- The Board of Directors resolved to recommend the payment of a final dividend of HK$0.02 per share for the year ended December 31, 2023.
- During the Reporting Period, the Group's investment in R&D amounted to RMB55.3 million, which increased as a percentage of operating revenue to 6.2% for the year ended December 31, 2023.